Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
LBT Innovations (ASX:LBT) share price plummets 14% despite positive update
Why the LBT Innovations share price is charging higher today
Why the LBT Innovations share price rocketed 243% higher on Tuesday
3 fast-growing biotech shares at the top of my watch list
Here’s why LBT Innovations Limited shares rocketed 89% today
What investors can learn from LBT Innovations Limited’s slump to a seven-month low
4 stocks that soared more than 16% today
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
LBT Innovations Ltd is a designer of advanced technology solutions for the medical industry. Its first product, MicroStreak, was a global first in the automation of the culture plate streaking process. Its second product, the Automated Plate Assessment System(APAS) is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis, and interpretation of microbiology culture plates following incubation.
|28 Jan 2022||$0.10||$0.00||0.00%||59,635||$0.10||$0.10||$0.10|
|27 Jan 2022||$0.10||$-0.01||-10.00%||798,499||$0.10||$0.10||$0.10|
|25 Jan 2022||$0.10||$0.00||0.00%||377,881||$0.11||$0.11||$0.10|
|24 Jan 2022||$0.11||$-0.01||-9.09%||205,670||$0.11||$0.11||$0.11|
|21 Jan 2022||$0.11||$-0.01||-8.70%||354,433||$0.12||$0.12||$0.11|
|20 Jan 2022||$0.12||$0.01||9.09%||33,050||$0.12||$0.12||$0.12|
|19 Jan 2022||$0.11||$0.00||0.00%||110,454||$0.11||$0.11||$0.11|
|18 Jan 2022||$0.11||$0.00||0.00%||26,440||$0.12||$0.12||$0.11|
|17 Jan 2022||$0.11||$-0.01||-8.33%||265,711||$0.12||$0.12||$0.11|
|14 Jan 2022||$0.12||$0.00||0.00%||215,709||$0.12||$0.12||$0.12|
|13 Jan 2022||$0.12||$0.00||0.00%||47,402||$0.12||$0.12||$0.12|
|12 Jan 2022||$0.12||$0.00||0.00%||112,648||$0.12||$0.12||$0.12|
|11 Jan 2022||$0.12||$0.00||0.00%||30,900||$0.12||$0.12||$0.12|
|10 Jan 2022||$0.12||$0.00||0.00%||282,553||$0.13||$0.13||$0.12|
|07 Jan 2022||$0.12||$0.00||0.00%||134,585||$0.12||$0.12||$0.12|
|06 Jan 2022||$0.12||$0.00||0.00%||433,793||$0.12||$0.12||$0.12|
|05 Jan 2022||$0.12||$0.00||0.00%||385,484||$0.12||$0.12||$0.12|
|04 Jan 2022||$0.12||$0.00||0.00%||427,639||$0.12||$0.13||$0.11|
|31 Dec 2021||$0.12||$0.02||20.41%||1,716,275||$0.11||$0.13||$0.11|
|30 Dec 2021||$0.10||$0.00||0.00%||1,378,711||$0.10||$0.10||$0.10|
|29 Dec 2021||Damian Lismore||Issued||68||$6,888||
|29 Dec 2021||Simon Arkell||Issued||57||$5,653||
|29 Dec 2021||Joanne Moss||Issued||1||$98,024||
Issue of options. Binomial valuation
|29 Dec 2021||Brian O'Dwyer||Issued||500||$36,688||
Issue of options. Binomial valuation
|Mr Damian Lismore||Non-Executive Director||Mar 2019||
Mr Lismore has held a number of Directorships and has commercial, international and listed company experience (both ASX and NASDAQ), covering many industries including healthcare and technology. In his Executive career, he held CEO, CFO and Company Secretarial roles and continues to act as an advisor to CEOs, boards and business owners. With a background in M&A, licensing and business financing, Damian has a track record in helping businesses grow. Damian is CFO of Scout Bio Inc, a Frazier Healthcare backed company, commercialising gene therapy products. Previously Damian was CFO at Nexvet Biophama plc, which attracted US institutional backing and listed on NASDAQ in 2015. The business evolved to have research capabilities in Australia, clinical operations in the US and manufacturing operations in Ireland. In 2017, following the successful completion of clinical trials for its lead program the business was acquired by Zoetis Inc. Damian was also CFO at Biota and was instrumental in securing and managing major licenses with global pharmaceutical companies and securing a major US grant that allowed the business to transition from the ASX to NASDAQ. Damian broadens the board skillset with his global outlook, networks and strong commercial acumen.
|Mr Brenton John Barnes||Chief Executive OfficerManaging Director||Aug 2016||
Mr Barnes is a global business Executive and medical technology enthusiast. He has broad experience in regulated Class I, Class II and Class III medical devices (implantable devices and artificial intelligence automation in healthcare), and in 2016 became CEO and Managing Director of LBT. Prior to this, Brent spent 11 years as a Senior Executive in a variety of roles at Cochlear Limited (ASX:COH), the global leader in implantable hearing devices. During his tenure with the company, he lived in the US, Singapore and Sydney, overseeing a range of global business functions. During this time, he was the Director Asia Growth Markets and Operations for Asia Pacific, growing the implantable hearing market across 12 countries in Asia over five years. In addition to his roles with LBT, Brent is a Non-Executive Director of Connek Pty Ltd, a telecommunications company that sub-contracts specialist services to leading blue chip telecommunications companies working on the national rollout of Australia's National Broadband Network.
|Mr Simon Arkell||Non-Executive Director||Jan 2019||
Mr Arkell is currently co-founder and President of Deep Lens, a US based artificial intelligence company focused on the deployment of a well known digital pathology platform to pathology labs worldwide with a focus on the identification of patients to clinical oncology trials. Deep Lens is backed by Northpoint Ventures, Sierra Ventures, Rev1 Ventures and Tamarind Hill Partners. Prior to Deep Lens, Simon was the GM of software platforms and analytics at Greenwave Systems, Inc. which acquired Predixion Software, the company Simon founded in 2009 and ran as CEO until its exit in September 2016. Predixion raised over $46 million from strategic and venture investors and was named a visionary for advanced analytics by Gartner in 2016. Prior to Predixion, Simon was an Operating Partner with Triton Pacific Capital Partners, was President and COO of an Oracle consulting company with 600 employees in 10 countries, was a Principal with boutique investment banking firm, and in 1998 he co-founded Versifi Technologies, Inc. in Newport Beach, California, a venture backed leader in the enterprise content management space. Simon is program Chairman for Megan's Wings, a children's cancer charity and serves on the boards of the President's Council and the Dean's Advisory Council for the Orfalea College of Business at Cal Poly San Luis Obispo. Originally from Adelaide, South Australia, Simon is also a two-time Olympian for Australia in the pole vault, and from 1990-1996 broke nine Australian and two Commonwealth records while also winning the gold medal at the 1990 Commonwealth Games. In 2015, Simon received the award for outstanding CEO for mid-sized companies at the Orange County Tech Alliance awards.
|Ms Joanne Moss||Non-Executive DirectorNon-Executive Chairman||Jul 2021||
Ms Moss has current board experience in the development, manufacture and commercialisation of medical devices and digital diagnostics. Ms Moss is an independent Non-Executive Director, Chair of Audit and Risk Committee, and Member of the Nominations and Remuneration Committee of award-winning Australian company, Ellume Limited. Ellume develops, manufactures and commercialises digital diagnostic products for consumers, healthcare professionals and laboratories. Ms Moss is an experienced senior executive with a background in legal advisory, risk, corporate governance, compliance and stakeholder engagement. Commencing her career at global law firm Norton Rose Fulbright, Ms Moss was an adviser to public and private companies across the corporate/M&A, banking and finance, infrastructure and commercial litigation practice groups. More recently, Ms Moss held the position of Chief Legal and Corporate Affairs Officer at Pizza Hut Australia, a brand within Fortune 500 company Yum!. In this board facing role, Ms Moss contributed to the company's commercial and digital transformation. Ms Moss has undertaken further studies at the Governance Institute of Australia and National Association of Company Directors in the US.
|Mr Brian O'Dwyer||Non-Executive Director||Oct 2021||
|Mr Ray Ridge||Chief Financial OfficerCompany Secretary||Feb 2020||
|Ray Ridge||Chief Financial OfficerCompany Secretary||
|P Bradley||VP of Global Business Development (General Manager CCS)||
|B Moran Pty Ltd||8,543,020||2.95%|
|Z & F International Trading Limited||6,451,613||2.23%|
|Mazoni Pty Ltd <The Utiger Super Fund A/C>||6,000,000||2.08%|
|Mr Robert Andrew Finder + Mrs Sheryl Jean Finder <Sherrob9 S/F A/C>||5,401,665||1.87%|
|Mr Peter James Davidson||4,326,103||1.50%|
|Dr Jiansheng Zhou||4,261,817||1.47%|
|Mr Hugh Berkeley Guthrie + Mrs Lucyna Halina Guthrie <Podlaska Super A/C>||3,535,385||1.22%|
|Mr Stephen Goodwin||3,500,000||1.21%|
|Mr David Mckay||3,456,632||1.20%|
|Mr Richard Anthony Earp||3,346,000||1.16%|
|Mr David Cattuzzo + Mrs Elizabeth Cattuzzo||3,100,000||1.07%|
|Ruin Pty Ltd <Steve Mathwin Super A/C>||3,005,262||1.04%|
|Kew Superannuation Fund Pty Ltd <K W Superannuation Fund A/C>||2,750,000||0.95%|
|Bearay Pty Ltd <Brian Clayton S/F A/C>||2,573,537||0.89%|
|Citicorp Nominees Pty Limited||2,418,642||0.84%|
|Morcap Pty Ltd <Cmc Lawyer S/F A/C>||1,955,645||0.68%|
|Mrs Jennifer Kay O'Mahony||1,921,036||0.66%|
|Mr James Edward Doyon||1,900,000||0.66%|
|Chag Pty Ltd||1,800,000||0.62%|